De novo discovery of a molecular glue–like macrocyclic peptide that induces MCL1 homodimerization
Proceedings of the National Academy of Sciences · 2025-04 · 122 (13)
DOI: 10.1073/pnas.2426006122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 25.03.2025. Verfasst von Fengwei Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao 266237, China. Hauptthemen laut MEDLINE: Myeloid Cell Leukemia Sequence 1 Protein, Protein Multimerization, Antineoplastic Agents, Peptides, Cyclic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
Macrocyclic peptides have emerged as promising drug candidates, filling the gap between small molecules and large biomolecules in drug discovery. The antiapoptotic protein myeloid cell leukemia 1 (MCL1) is crucial for numerous cancers, yet it presents challenges for selective targeting by traditional inhibitors. In this study, we identified a macrocyclic peptide, 5L1, that strongly binds to MCL1, with a dissociation constant ( K D ) of 7.1 nM. This peptide shows the potential to specifically inhibit the function of MCL1, and demonstrates effective antitumor activity against several blood tumor cell lines with the half maximal inhibitory concentration (IC 50 ) values for cell-penetrating peptide-conjugated 5L1 in the range of 0.6 to 3 μM. Structural analysis revealed that it functions similarly to molecular glue, capable of binding to two MCL1 molecules simultaneously and inducing their homodimerization. This unique mechanism of action distinguishes it from traditional small-molecule MCL1 inhibitors, underscoring the potential of macrocyclic peptides functioning as molecular glues. Moreover, it inspires the development of highly selective inhibitors targeting MCL1 and other related targets with this glue-like mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao 266237, China.
- Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Shandong Energy Institute, Qingdao New Energy Shandong Laboratory, Qingdao 266061, China.
- Shanghai Zelixir Biotech Company Ltd., Shanghai 200030, China.
- Waters | Wyatt Technology, Beijing 100176, China.
- Shandong Research Institute of Industrial Technology, Jinan 250101, China.
ORCID-Profile: Fengwei Li, Dalei Wu, Yizhen Yin
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
Zitieren
APA
Li, F., Zhang, M., Liu, C., Cheng, J., Yang, Y., Peng, X., Li, Z., Cai, W., Yu, H., Wu, J., Guo, Y., Geng, H., Fa, Y., Zhang, Y., Wu, D., & Yin, Y. (2025). De novo discovery of a molecular glue–like macrocyclic peptide that induces MCL1 homodimerization. Proceedings of the National Academy of Sciences, 122(13). https://doi.org/10.1073/pnas.2426006122
Vancouver
Li F, Zhang M, Liu C, Cheng J, Yang Y, Peng X, et al. De novo discovery of a molecular glue–like macrocyclic peptide that induces MCL1 homodimerization. Proceedings of the National Academy of Sciences. 2025;122(13). doi:10.1073/pnas.2426006122
BibTeX
@article{Li2025,
author = {Li, Fengwei and Zhang, Mengmeng and Liu, Chao and Cheng, Jie and Yang, Yawen and Peng, Xiangda and Li, Zhifeng and Cai, Wenfeng and Yu, Haipeng and Wu, Junjie and Guo, Yuyu and Geng, Hongkun and Fa, Yun and Zhang, Youming and Wu, Dalei and Yin, Yizhen},
title = {De novo discovery of a molecular glue–like macrocyclic peptide that induces MCL1 homodimerization},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {13},
doi = {10.1073/pnas.2426006122}
}
EUVIMED